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Intraamniotic inflammation is associated with up to 40% of preterm births, most notably in
deliveries occurring prior to 32 weeks’ gestation. Despite this, there are few treatment
options allowing the prevention of preterm birth and associated fetal injury. Recent studies
have shown that the small, non-competitive allosteric interleukin (IL)-1 receptor inhibitor, ryt-
vela, may be of use in resolving inflammation associated with preterm birth (PTB) and fetal
injury. We aimed to use an extremely preterm sheep model of chorioamnionitis to investi-
gate the anti-inflammatory efficacy of rytvela in response to established intra-amniotic (IA)
lipopolysaccharide (LPS) exposure. We hypothesized that rytvela would reduce LPS-
induced IA inflammation in amniotic fluid (AF) and fetal tissues.
Methods
Sheep with a single fetus at 95 days gestation (estimated fetal weight 1.0 kg) had surgery to
place fetal jugular and IA catheters. Animals were recovered for 48 hours before being ran-
domized to either: i) IA administration of 2 ml saline 24 hours before 2 ml IA and 2 ml fetal
intravenous (IV) administration of saline (Saline Group, n = 7); ii) IA administration of 10 mg
LPS in 2 ml saline 24 hours before 2 ml IA and 2 ml fetal IV saline (LPS Group, n = 10); 3) IA
administration of 10 mg LPS in 2 ml saline 24 hours before 0.3 mg/fetal kg IA and 1 mg/fetal
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kg fetal IV rytvela in 2 ml saline, respectively (LPS + rytvela Group, n = 7). Serial AF samples
were collected for 120 h. Inflammatory responses were characterized by quantitative poly-
merase chain reaction (qPCR), histology, fluorescent immunohistochemistry, enzyme-
linked inmmunosorbent assay (ELISA), fluorescent western blotting and blood chemistry
analysis.
Results
LPS-treated animals had endotoxin and AF monocyte chemoattractant protein (MCP)-1
concentrations that were significantly higher at 24 hours (immediately prior to rytvela admin-
istration) relative to values from Saline Group animals. Following rytvela administration, the
average MCP-1 concentrations in the AF were significantly lower in the LPS + rytvela Group
relative to in the LPS Group. In delivery samples, the expression of IL-1β in fetal skin was
significantly lower in the LPS + rytvela Group compared to the LPS Group.
Conclusion
A single dose of rytvela was associated with partial, modest inhibition in the expression of a
panel of cytokines/chemokines in fetal tissues undergoing an active inflammatory response.
Background
Preterm birth (PTB; delivery before 37 weeks of completed gestation) is a major cause of neo-
natal mortality and morbidity, with the greatest rates of death and significant disease seen in
premature deliveries occurring prior to 32 weeks’ gestation [1, 2]. PTB is a multifactorial syn-
drome [1, 2]. Many studies have investigated the role of intraamniotic inflammation in PTB;
comparatively few studies have evaluated the efficacy of antenatal treatments for infection and
inflammation-associated prematurity [1, 3, 4].
Interleukin (IL)-1 is a potent pro-inflammatory cytokine, [4, 5]. IL-1β concentration and
bioactivity in amniotic fluid of women is related to preterm labor (PTL), infection [6], and
PTB [7]. Intra-amniotic (IA) injection of 10 mg lipopolysaccharide (LPS) caused elevated con-
centrations of IL-1 in the amniotic fluid, chorioamnionitis, lung inflammation, and systemic
inflammation in studies using preterm ovine model. Several studies have previously reported
investigations into the efficacy of IL-1 targeting agents to prevent PTB and fetal injury [4, 5],
using agents that competitively antagonize the IL-1 receptor and therefore likely block all
downstream IL-1 signal transduction, including NF-κB activation [4]. This approach may risk
interruption to important physiological processes such as cytoprotection and immune-surveil-
lance [8].
Rytvela is a selective allosteric inhibitor of IL-1 receptor signalling [9, 10]. Allosteric antago-
nists interact with the receptor at a site remote from the orthosteric binding site, allowing the
ligand to bind its receptor. They are biased signal inhibitors; i.e. they selectively inhibit some
but not all intracellular signals of the receptor [11, 12]. A previous study showed rytvela selec-
tively inhibited IL-1Racp downstream stress-associated protein kinase JNK, mitogen-activated
protein kinases p38 and Rho/Rho GTPase/Rho-associated coiled-coil-protein kinase pathway,
without affecting NF-κB activation [9]. Therefore, unlike other IL-1-targeting agents, rytvela
can exert functional selectivity [11]. Accordingly, rytvela likely does not inhibit NF-κB [10] or
suppress immune-surveillance. Due to its small size, rytvela is expected to have good
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bioavailability [13]. Recent studies demonstrated that rytvela (1 mg/kg) reduced PTB and peri-
natal death, and reduced inflammation in the fetal brain, lung and colon of mice exposed to
LPS [4, 9, 10]. No evidence of reproductive toxicity was detected and rytvela was shown to
have a promising pharmacological profile [4, 5, 10].
It remains to be determined if rytvela allows for control of established intrauterine inflam-
mation in extremely preterm fetal lambs–an established model for human fetal inflammation/
infection. Making this determination is important because: i) patients in preterm labour are
commonly diagnosed with intrauterine infection / inflammation after already presenting with
symptoms; and ii) infection and inflammation are most commonly associated with early pre-
term delivery and fetal injury. In this experiment, rytvela was administrated to extremely pre-
term ovine fetuses 24 hours after LPS exposure to simulate a potential clinical intervention
scenario. While clinically rytvela would be given maternally, in this study direct fetal and
intramniotic administration of rytvela was employed to ensure accurate intraamniotic dosing.
We hypothesized that antenatal administration of rytvela treatment would reduce intra-amni-
otic and fetal inflammation.
Methods
Animals
Animal studies were approved by The University of Western Australia’s Animal Ethics Com-
mittee (approval RA.3.100.1638). Ewes with a singleton fetus at 95 days of gestation (term is
~150 days) were fasted overnight before undergoing recovery surgery to place fetal jugular and
intra-amniotic (IA) catheters, as previously reported [14]. After a 48-hour recovery, animals
were randomized to one of the following groups (Fig 1): i) a single IA bolus of 2 ml saline 24
hours before both 2 ml IA and 2 ml fetal intravenous (IV) injection of saline (Saline Group,
n = 7); ii) IA injection of 10 mg LPS from Escherichia coli (055:B5; Sigma Aldrich, St Louis,
Missouri) in 2 ml saline 24 hours before 2 ml IA and 2 ml fetal IV injection of saline (LPS
Group, n = 10); 3) IA injection of LPS in 2 ml saline 24 hours before 0.3 mg/kg IA and 1 mg/
kg fetal IV injection of rytvela, both in 2 ml saline vehicle (LPS + rytvela Group, n = 7). Rytvela
was administered into the fetal circulation and amniotic cavity to target systemic and localized
(amniotic fluid-exposed) inflammation, with dosing based on previous efficacious use in a
Fig 1. Study design. The LPS Group and the LPS + Rytvela Group animals received an IA injection of 10 mg LPS at 0 hour. The
Saline Group animals received an equivalent volume of saline solution. The LPS + rytvela Group received both IA and fetal
intravenous injection of rytvela at 24 hours after LPS exposure. The Saline Group and the LPS Group animals received an equivalent
volume of saline solution. IA, intra-amniotic; LPS, lipopolysaccharide; MCP, monocyte chemoattractant protein.
https://doi.org/10.1371/journal.pone.0257847.g001
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small animal model [5, 9, 10]. Animal wellbeing was monitored daily, with free access to food
and water.
Amniotic fluid (AF) was serially sampled from amniotic catheters at 0, 12, 24, 48, 72, and
120 hours after the first administration of either saline or LPS. Animals were euthanized with
an intravenous bolus (160 mg/kg) of pentobarbital at 120 hours. Fetal cord blood was collected
at delivery for blood chemistry and ELISA analysis. Fetal tissues were snap frozen in liquid
nitrogen for protein or messenger ribonuclease acid (mRNA) expression analyses. For histo-
logical analyses, fetal tissue was placed in cassettes and fixed in 10% neutral buffered formalin
before being processed by paraffin embedding.
Endotoxin quantification
Endotoxin concentrations in amniotic fluid were measured by using a Pierce™ Chromogenic
Endotoxin Quant Kit (Thermo Fisher, A39552), according to manufacturer’s instructions.
Each plate was read at 405 nm on a Spectramax plate reader (Molecular Devices LLC, Sunny-
vale, CA).
Enzyme-linked inmmunosorbent assay
Quantification of the cytokine IL-1 in amniotic fluid, cord blood at delivery, and fetal lung and
IL-8 in amniotic fluid and cord plasma were measured by using a Sheep ELISA Kits (CUSA-
BIO, CSB-E10115Sh), according to manufacturer’s protocols. Each plate was read at 450 nm
on a Spectramax plate reader (Molecular Devices LLC, Sunnyvale, CA). The software package
Curve Expert, version 1.4 (CUSABIO), was used to make a standard curve. Similarly, quantifi-
cation of the chemokine monocyte chemoattractant protein (MCP)-1 and cytokine tumor
necrosis factor (TNF)-α in amniotic fluid and cord plasma were measured by using a King-
fisher Biotech (Saint Paul, MN) ELISA Development Kits, according to the manufacture’s pro-
tocol. Each plate was read at 450 nm on a Spectramax plate reader (Molecular Devices LLC,
Sunnyvale, CA).
Tissue RNA isolation
DNA-free total RNA was isolated from frozen fetal tissues (lung right lower lobe, internal
groin skin, colon, chorioamnion and brain cortex) using RNeasy1 Plus Mini Kit (QIAGEN,
Hilden, Germany), according to the manufacture’s protocol. The concentration and quality of
extracted RNA was quantified with a Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA).
Quantitative polymerase chain reaction
Ovine-specific PCR primers and hydrolysis probes for IL-1β, IL-6, TNF-α and MCP-1 (Ther-
mofisher) were used to perform quantitative PCR reactions on RNA from fetal lung, skin,
colon, chorioamnion and brain cortex tissue. Fetal lung, skin, chorioamnion and colon were
selected for analysis as they are exposed to the amniotic fluid directly or via swallowing and
have been shown to initiative a pro-inflammatory response following IA LPS administration.
Inflammation of the fetal brain in the setting of preterm birth is of significant interest given its
association with neuro-developmental damage.
Reactions were conducted using a Step One Real-Time PCR system and probe/primer sets
from Life Technologies with RNA normalised to 25 ng/μl. Reaction cycling conditions were as
follows: 1 × 15 min reverse transcription [50˚C], 1 × 20 seconds initial denaturation [95˚C],
followed by 40 cycles of 3 seconds denaturation [95˚C] and 30 seconds annealing [60˚C]. All
reactions were performed in 96 well fast plates on a ViiA7 real-time PCR themocycler (Life
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Technologies) and in triplicate. Averaged quantitation cycle (Cq) values were normalized
against averaged Cq values of ribosomal protein 18s. Data were processed to generate fold
changes using a 2-ddCq method and were tested for significance.
Histology of fetal lung and chorion-amnion
The right upper lobe of each lung was inflation fixed with 4% paraformaldehyde at 30 cmH2O
pressure. The inflammation of both fetal lung and chorion-amnion was evaluated using hema-
toxylin and eosin (H&E)-stained sections and was graded in a blinded fashion by a scoring
methods follows: Fetal lung was assessed using three 5-μm sections from each animal as 0 (no
inflammatory cells), 1 (a few inflammatory cells), 2 (moderate influx of cells) or 3 (extensive
influx of inflammatory cells), as previously published [15, 16].
Chorioamnion rolls were fixed in 4% paraformaldehyde. Chorioamnionitis was classified
using a modified grading system based on that reported by Redline et. al. [17]. Histological
staining was used to determine the localization of inflammatory cells and (where present) tis-
sue damage. The grade evaluation also identifies the intensity of the inflammatory cell infiltra-
tion [17, 18]. The chorioamnion of each animal was graded based on this classification as
previously reported [19]: 0 (no chorioamnionitis), 1 (localization: within choriodecidua; inten-
sity: individual or small clusters of inflammation cell), 2 (localization: within choriodecidua;
intensity: the three or more chorionic microabscesses which are defined as inflammatory
cell� 10 × 20 cells), 3 (localization: choriodecidua and/or amnion, intensity: same as score =
2), 4 (localization: necrosis of the amniotic epithelium; intensity: same as score = 2). Six 5-μm
sections from each animal were evaluated at random and an average score was calculated for
each animal.
Fluorescent immunohistochemical analysis of fetal brain
The left hemisphere was fixed in 4% paraformaldehyde and sectioned in 4-mm serial section
(5 serial sections in total) along the coronal plane from the anterior to posterior sections
according to the method of Banker and Larroche [20]. The second serial section was selected
to be embedded in paraffin and stained using following primary antibodies: glial fibrillary
acidic protein (GFAP) (1:1000, ab7260, Abcam), ionized calcium-binding adapter molecule 1
(Iba-1) (1:500, ab178846, Abcam), oligodendrocyte transcription factor 2 (Olig-2) (1:2000,
NBP1-28667, Novusbio) and neuronal nuclei (NeuN) (1:750, ab128886, Abcam). Alexa
Fluor1 488 (1:10000, ab150077, Abcam) was used as secondary antibody and nuclei were
stained with DAPI (F6057, Sigma-Aldrich). Microphotographs were captured using a confocal
microscope (Nikon A1Si). Five random, non-overlapping fields per section were assessed for
each antigen target. Numbers of GFAP-, Iba-1-, Olig-2- and NeuN-positive / DAPI-positive
cells in subcortical white matter were counted manually by single investigator blinded to
treatment.
Western blot analysis of fetal brain tissue
Proteins from the right hemisphere cortex were extracted using RIPA lysis buffer (Thermo
Fisher, 89901) and a cocktail of protease inhibitors (Merck, 04693116001) following cold mac-
eration on a Precellys 24 tissue homogenizer. Protein concentration was quantified with a
Pierce™ Rapid Gold BCA Protein Assay Kit (Thermo Fisher, A53226). 15 μg of total protein
per well was resolved using a NuPAGE™ 10% Bris-Tris Gel and electrotransferred to PVDF
membrane according to manufacturer’s instructions. Membranes were blocked with blocking
buffer (Thermo Fisher, 37565) for 30 minutes at room temperature and incubated with No-
Stain™ Protein labeling Reagent (A44717, Thermo Fisher) according to the manufacture’s
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instructions. Membranes were then incubated overnight at 4˚C on a rocker platform with fol-
lowing primary antibodies: GFAP (1:5000, ab7260, Abcam), Iba-1 (1:1000, ab178846, Abcam),
Olig-2 (1:3000, NBP1-28667, Novusbio) and NeuN (1:1000, ab128886, Abcam). Western blot
enhancer (SuperSignal™ Western Blot Enhancer, 46640, Thermo Fisher) was used for Olig-2
according to the manufacture’s protocol. Membranes were washed for 30 minutes in PBS-
Tween before being incubated with Alexa Fluor1 488 (1:10000, ab150077, Abcam) for 1 hour
at room temperature. Membranes was analyzed with iBright™ FL1000 imaging system
(Thermo Fisher). Each band volume was normalized against the total protein amounts and
each membrane was compensated by the total protein amounts of quality control animal.
Hematology
Complete blood counts (CBC) were performed by VetPath Laboratory Services using an auto-
mated Coulter counter customized for sheep (Ascot, Perth, Western Australia).
Statistical analysis
Data were analysed for distribution, variance and skew. All values are expressed as either
mean ± one standard deviation or median ± IQR. Analyses were performed using IBM SPSS
Statistics for Windows, version 20.0 (IBM Corp. Armonk, NY.). Paired comparisons were per-
formed with t-tests or Mann-Whitney tests. The comparison of more than two groups was
tested by one-way ANOVA analysis of variance with multiple post-hoc comparisons used by
Tukey’s t or Kruskal-Wallis post-hoc analyses. Significance was accepted at p< 0.05.
Results
There were no significant differences in birthweight, cord blood pH, pCO2, or lactate at deliv-
ery between the three treatment groups (Table 1). No increase of fetal edema or ascites as a
result of lipopolysaccharide exposure or rytvela administration was detected. Variability in the
group sizes used to analyse time-course samples obtained by catheter sampling reflect changes
in fetal positioning which impact catheter patency.
Endotoxin quantification
Endotoxin concentrations from the LPS-treated Groups (the LPS Group and the LPS + rytvela
Group) at 10 hours after LPS administration in AF were significantly increased compared to
AF samples from the Saline Group. (Saline Group vs. LPS-treated Groups p<0.000) (Fig 2A).
ELISA
Pre-intervention analysis. We evaluated the effect of IA administration of LPS or saline
from 0 to 24 hours (before randomization to treatment by either saline or rytvela). No differ-
ence was detected in AF concentrations in IL-1β, IL-8, MCP-1 or TNF-α at 0 hours between
the Saline-treated and LPS-treated animals. AF MCP-1 concentrations in the LPS-treated
Table 1. Delivery data.
Arterial fetal arterial cord blood
Group Sex (M/F) Delivery Wt. (kg) pH pCO2 (mmHg) Lactate (mmol/L)
Saline Group (n = 7) 3/4 1.1 ± 0.1 7.1 ± 0.1 78.0 ± 8.5 4.4 ± 0.9
LPS Group (n = 10) 6/4 1.2 ± 0.2 7.1 ± 0.1 75.8 ± 9.1 4.1 ± 1.3
LPS + Rytvela Group (n = 7) 7/0 1.2 ± 0.1 7.1 ± 0.1 81.3 ± 13.9 4.4 ± 1.1
https://doi.org/10.1371/journal.pone.0257847.t001
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animals increased significantly at 24 hours compared with Saline-treated animals (p = 0.016)
(Fig 2B). No significant differences were detected in IL-1β, IL-8 and TNF-α concentrations in
AF between Saline-treated animals and LPS-treated animals at 24 hours.
Post-intervention analysis. We then compared the average concentration of cytokines/
chemokines at time points between the LPS Group and the LPS + rytvela Group (Fig 3). The
average MCP-1 concentration in AF from the LPS + rytvela Group decreased significantly
compared to the LPS Group (p = 0.002) (Fig 3B). There were no significant differences in IL-
1β, IL-8 and TNF-α AF concentrations (Fig 3A, 3C and 3D).
At delivery. There was a significant difference in IL-1β protein concentration in fetal lung
tissue at delivery between the Saline Group and the LPS Group (p = 0.023). No difference was
detected between the Saline Group and the LPS + rytvela Group (p = 0.129) (Fig 4).
qPCR
Results are shown in Fig 5. Statistically significant increases were detected in fetal lung IL-1β
mRNA in both the LPS and LPS + rytvela Groups relative to the Saline Group animals (Saline
Group vs. LPS Group p = 0.043; Saline Group vs. LPS + rytvela Group p = 0.02). TNF-α
mRNA in the fetal lung was significantly increased in the LPS + rytvela Group animals com-
pared to the Saline Group animals (Saline Group vs. LPS + rytvela Group p = 0.029) (Fig 6A).
IL-1β mRNA in the fetal skin increased significantly in the LPS Group in comparison to the
Saline Group (Saline Group vs. LPS Group p = 0.004). Moreover, IL-1β mRNA concentration
in fetal skin was significantly lower in the LPS + rytvela Group compared to the LPS Group
(LPS Group vs. LPS + Rytvela Group p = 0.002) (Fig 6B).
Fig 2. A. Endotoxin concentrations in amniotic fluid. Plots show median, 25th, and 75th percentile ranges of AF endotoxin
concentrations at 24 hours post-administration as boxes and 5th to 95th percentile as error bars. �p< .05 vs. the Saline Group.
n = 6–10 animals/group. AF, amniotic fluid; LPS, lipopolysaccharide. B. Cytokines/chemokine concentrations in amniotic fluid from
0 to 24 hours after either saline or LPS. A, amniotic fluid IL-1β, IL-8, MCP-1, and TNF-α concentrations. �p< .05 between the
Saline Group and the LPS-treated Groups (LPS Group and LPS + rytvela Group). Plots show median, 25th, and 75th percentile
ranges as boxes and 5th to 95th percentile as error bars. n = 4–8 animals/group. AF, amniotic fluid; LPS, lipopolysaccharide; ELISA,
Enzyme-linked inmmunosorbent assay.
https://doi.org/10.1371/journal.pone.0257847.g002
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The LPS Group had a significant increase in fetal skin TNF-α mRNA concentration com-
pared with the Saline Group animals (Saline Group vs. LPS Group p = 0.016) (Fig 6B). Similar
to fetal lung and skin, there were significant increases in IL-1β mRNA in the colon of LPS
Group animals relative to the Saline Group animals (Saline Group vs. LPS Group p = 0.045)
(Fig 6C). No differences were identified in TNF-α mRNA concentration in colon tissue
between the three groups.
There were no significant differences in fetal chorioamnion in IL-1β mRNA concentration
among the three groups; however, significant increases were detected in TNF-α mRNA con-
centration in the chorion-amnion of both the LPS Group and the LPS + rytvela Group animals
relative to the Saline Group animals (Saline Group vs. LPS Group p = 0.01; Saline Group vs.
LPS + Rytvela Group p = 0.03) (Fig 6D). There were no differences in IL-1β, TNF-α, IL-6 or
MCP-1 mRNA detected in fetal brain (cortex), among the three groups (Fig 6E).
Histology and fluorescent immunohistochemistry
Inflammation in the fetal lung and chorioamnion was evaluated by blind scoring of inflamma-
tory cells by a single investigator. Inflammatory cell infiltration was detected in fetal lung in
both the LPS Group and the LPS + rytvela Group; in contrast, few or no inflammatory cells
were detected in the Saline Group animals (Fig 5B to 5D for representative images). The
inflammation score of the LPS Group was significantly higher than that of the Saline Group,
while there was no significant difference between the Saline Group and the LPS + rytvela
Group animals (Saline Group vs. LPS Group p = 0.005; Saline Group vs. LPS + rytvela Group
p = 0.142) (Fig 5A).
Similarly, inflammatory cells were detected in the chorion-amnion of both the LPS Group
and the LPS + rytvela Group (Fig 7B to 7D for representative images). The inflammation score
was significantly increased in the LPS Group relative to the Saline Group (Saline Group vs.
Fig 3. Cytokines/chemokine concentrations in amniotic fluid after the administration of either saline or rytvela). Cytokines/
chemokine concentration in AF at each time point plotted as mean ± SD. Each group’s average concentration is shown in bar charts.
A, IL-1β; B, MCP-1; C, IL-8; D, TNF-α. The average concentration was compared between the LPS Group and the LPS + rytvela
Group. �p< .05 between the LPS Group and the LPS + rytvela Group. n = 3–7 animals/group. AF, amniotic fluid; SD, standard
deviation; IL, Interleukin; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor.
https://doi.org/10.1371/journal.pone.0257847.g003
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LPS Group p = 0.006). The inflammation score in the LPS + rytvela Group was comparable to
that of the Saline Group (Saline Group vs. LPS + Rytvela Group p = 0.23) (Fig 7A).
Fluorescent immunohistochemistry and western blotting was performed to assess fetal
brain injury. Previous studies showed the reaction of fetal brain exposed to LPS are activated
microglia and astrocyte, maturation arrest or death of oligodendrocyte, and axonal loss or
death of neurons [21–23]. Therefore, as for analysis of the cortex, inflammation/injury was
assessed by counting Iba-1-, GFAP-, Olig-2- and NeuN-positive / DAPI positive cells in sub-
cortical white matter. There were no significant differences in the numbers of Iba-1-, GFAP-,
Olig-2-, and NeuN-positive / DAPI positive cells in subcortical white matter among the three
groups. (Fig 8A).
Fluorescent western blotting
Results are shown in Fig 8B. Iba-1, GFAP, Olig-2 and NeuN specific bands (green bands) were
observed and each band volume was normalized to total protein amounts (blue bands). There
Fig 4. IL-1β protein concentrations in fetal lung at delivery. �p< .05 vs. the Saline Group. Plots show median, 25th, and 75th
percentile ranges as boxes and 5th to 95th percentile as error bars. n = 7–10 animals/group IL, Interleukin.
https://doi.org/10.1371/journal.pone.0257847.g004
PLOS ONE Transient resolution of inflammation with rytvela
PLOS ONE | https://doi.org/10.1371/journal.pone.0257847 September 24, 2021 9 / 18
was no significant differences of the band volume of Iba-1, GFAP, Olig-2 and NeuN in fetal
cortex (Fig 8B) between groups.
Haematology
There was a significant increase in the total white blood cell count at delivery in both the LPS
Group and the LPS + rytvela Group fetuses relative to the Saline Group animals (Saline Group
vs. LPS Group p = 0.036; Saline Group vs. LPS + rytvela Group p = 0.029) (Fig 9A). Similarly,
the ratio of fetal neutrophils to total white blood cells at delivery was significantly increased in
both the LPS Group and the LPS + rytvela Group animals compared with the Saline Group
animals (Saline Group vs. LPS Group p = 0.001; Saline Group vs. LPS + Rytvela Group
p = 0.001). The ratio of lymphocytes to total white blood cells was significantly decreased in
both the LPS Group and the LPS + rytvela Group animals when compared with the Saline
Group animals (Saline Group vs. LPS Group p = 0.003; Saline Group vs. LPS + rytvela Group
p = 0.001) (Fig 9B and 9C).
Discussion
Primary findings
These data show that, in extremely preterm sheep fetuses, the introduction of LPS to the amni-
otic cavity induced chorioamnionitis and increased tissue inflammation. The combined
intraamniotic and fetal intravenous administration of rytvela was associated with a modest
partial reduction in fetal and intraamniotic inflammation even 24 hours following LPS
exposure, relative to treatment with saline only. As such, with further optimization (dose,
Fig 5. Histological assessment of fetal lung. A, Plots show median, 25th, and 75th percentile ranges as boxes and 5th to 95th
percentile as error bars. LPS Group increased inflammation score in fetal lung tissue relative to Saline Group. �p< .05 between the
Saline Group and the LPS Group. Representative sections of tissue from B, Saline Group (score = 0); C, LPS Group (score = 2); D,
LPS + rytvela Group (score = 1). Inflammatory cells are indicated by arrows. Scale bar: 100 μm. n = 7–10 animals/group. LPS,
lipopolysaccharide.
https://doi.org/10.1371/journal.pone.0257847.g005
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timing, route of administration) of rytvela may show promise as treatment for intra-amniotic
inflammation.
Results
Amniotic fluid inflammation. LPS-associated increases in TNF-α expression were noted
in fetal tissues, although not in the AF as previously reported [24]. Similarly, differences in IL-
1β expression were only detected in fetal tissue. Previous studies found that IL-1β induced
MCP-1 expression in human cells via both NF-κB-mediated and alternative signaling path-
ways [25], while significantly increased MCP-1 concentration in the AF of women were associ-
ated with evidence of intra-amniotic infection [26]. Moreover, studies have also shown that
the concentration of MCP-1 in AF from women who delivered preterm without apparent
intra-amniotic infection was significantly higher than those who delivered at term delivery
[26, 27]. Therefore, MCP-1 is a useful biomarker to the existence of intraamniotic infection
regardless of whether the antigen is identified or not. The amount of MCP-1 protein detected
was significantly elevated in the LPS-treated animals compared with the Saline Group. More-
over, in the LPS + rytvela Group, MCP-1 average AF concentrations were significantly
decreased, relative to values in the LPS Group, suggesting a partial inhibition of inflammation
in response to rytvela treatment. We and others have previously demonstrated that extended
exposure to intrauterine inflammation negatively affects fetal outcome [15, 21, 28]. As such,
reduction of intraamniotic inflammation may reduce the risk and/or severity of fetal injury.
Fig 6. Messenger RNA expression in at delivery. Relative expression of mRNA transcripts for IL-1β, IL-6, MCP-1, and TNF-α in A,
fetal lung; B, skin; C, colon; D, chorioamnion; E, cortex. †p< .05 vs the Saline Group. �p< .05 between the LPS Group and the
LPS + rytvela Group. Plots show median, 25th, and 75th percentile ranges as boxes and 5th to 95th percentile as error bars. n = 7–10
animals/group. IL, Interleukin; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor.
https://doi.org/10.1371/journal.pone.0257847.g006
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No statistically significant increase in either IL-1β or IL-8 was detected in the AF between
LPS and non-LPS groups prior to treatment. Although this reason for this observation is not
known exactly, it is possible that the timing of sampling was too early or too late to optimally
capture increase expression. It is also possible that an increase in baseline inflammation deriv-
ing from fetal and maternal surgery increased the noise in the analysis, partly masking a differ-
ence in AF inflammation between groups.
Fetal tissue inflammation. Animals in the LPS Group had significant increases in IL-1β
mRNA expression in all three organs assessed (skin, lung and colon) that were exposed to the
AF (and thus directly to LPS), compared to the Saline Group, whereas there were no differ-
ences detected between the LPS + rytvela Group and the Saline Group animals, suggesting
some degree of resolution of inflammation signaling by rytvela. Similarly, ELISA results
showed that IL-1β concentrations in fetal lung from the LPS Group were significantly
increased compared to the Saline Group, while no difference was found between the LPS + ryt-
vela Group and the Saline Group.
The LPS Group and the LPS + rytvela Group animals both had significantly increased WBC
counts and altered neutrophil and lymphocyte ratios. Histopathological evaluation of the fetal
lung and the chorioamnion also showed the inflammation score increased significantly in the
LPS Group compared to the Saline Group, while there was no significant differences between
the LPS + rytvela Group and the Saline Group–although the range of scores therein was
increased. Moreover, IL-1β mRNA expression in the skin of fetuses in the LPS + rytvela Group
Fig 7. Histological assessment of chorioamnion. A, Plots show median, 25th, and 75th percentile ranges as boxes and 5th to 95th
percentiles as error bars. The LPS Group increased inflammation score in chorion-amnion tissue relative to the Saline Group. �p<
.05 between the Saline Group and the LPS Group. Representative sections of tissue from B, Saline Group (score = 0); C, LPS Group
(score = 2); D, LPS + rytvela Group (score = 1). Scale bar: 100 μm. n = 7–10 animals/group. LPS, lipopolysaccharide.
https://doi.org/10.1371/journal.pone.0257847.g007
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was significantly lower than that of animals from the LPS Group. Previous studies have identi-
fied the fetal skin is as a pro-inflammatory organ following intrauterine endotoxin exposure in
the preterm sheep [29, 30]. We previously demonstrated that selective exposure of fetal skin +
amnion to LPS induce acute systemic inflammation [31] and significant elevation of mRNA
expression for IL-1β in fetal skin persisted till 15 days after LPS exposure [32], while that in
Fig 8. Fluorescent immunohistochemistry and western blotting assessment of fetal brain. A, Representative photomicrographs
show Iba-1-, GFAP-, Olig-2- and NeuN- positive (green) / DAPI positive (blue) cells in subcortical white matter of the Saline Group
animals. Positive cells are indicated by arrows. Scale bar: 50 μm. Box plots show the numbers of counting Iba-1-, GFAP-, Olig-2- and
NeuN- positive / DAPI positive cells of three groups. B, Representative images show Iba-1, GFAP, Olig-2 and NeuN specific band
(green) and total protein stained band (blue) of the quality control animal (Saline Group animal). Box plot show the band volume of
the each antibody against the total protein amounts. Plots show median, 25th, and 75th percentile ranges as boxes and 5th to 95th
percentile as error bars. n = 6–8 animals/group. Iba-1, ionized calcium-binding adapter molecule 1; GFAP, glial fibrillary acidic
protein; Olig-2, oligodendrocyte transcription factor 2; NeuN, neuronal nuclei.
https://doi.org/10.1371/journal.pone.0257847.g008
Fig 9. Haematological assessments. Plots show median, 25th, and 75th percentile ranges as boxes and 5th to 95th percentile as error
bars. Intra-amniotic injection of LPS affected A, total white blood cell (WBC) counts; B, ratio of neutrophil; C, ratio of lymphocyte
from cord blood. LPS, lipopolysaccharide. n = 7–9 animals/group.
https://doi.org/10.1371/journal.pone.0257847.g009
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fetal lung persisted till only 2days after LPS exposure [15]. As such, significant decrease of IL-
1β mRNA expression in rytvela-treated fetal skin can be taken as suggestive of a beneficial
effect of rytvela.
Taken together, these data suggest a modest reduction in fetal inflammation associated with
the administration of rytvela. Given the exploratory nature of the dosing employed in this
study and the persistent half-life of endotoxin in the intraamniotic environment, more fre-
quent administration of rytvela may offer improved dampening of inflammatory responses.
Clinical implications
It is widely accepted that intra-amniotic infection can cause acute neonatal mortality as well as
long-term adverse outcomes. Currently, if the intra-amniotic infection and inflammation are
suspected on the basis of a patient presenting with maternal fever, vaginal discharge, fetal dis-
tress or PTL, responses are broadly limited to the use of antibiotics and/or the management of
delivery. A means of rapidly resolving intrauterine inflammation would be of potential use
and likely to improve neonatal outcomes.
There have been several studies investigating the efficacy of IL-1 targeting agents to prevent
PTB and fetal injury [4, 5, 9, 10]. The agents used in these previous studies all antagonized IL-1
actions competitively and blocked all downstream signal transduction [4], including that of
NF-κB; this is thought to affect immune-surveillance and may result in an increased risk of
fetal and maternal infection [8, 33]. Therefore, the functional selectivity of rytvela may allow
for a reduction in the risk of adverse effects.
Agents such as rytvela regulate inflammatory responses but do not resolve the underlying
infection or sequester pro-inflammatory antigen (in contrast to antibiotics such as polymyxin-
B). These agents also have limited half-lives in vivo. Thus, any efficacious treatment regimen
will likely be multi-faceted to allow for resolution of infection, inflammation signaling, and
inhibition of further inflammatory stimulation. Additionally, in clinical practice there is a lack
of effective and established diagnostic tests for women who are at risk of intra-amniotic infec-
tion leading to PTB, especially before 32 weeks gestation. As such, the successful application of
agents such as rytvela (in combination with antimicrobial agents) will likely require a tandem
improvement in the reliability of diagnostic tests for women at risk of intrauterine infection
and PTL.
Research implications
This study suggests potential efficacy of rytvela for treatment of intraamniotic infection during
pregnancy. It is unclear whether IA or IV administration alone was sufficient for transient res-
olution of inflammation, or whether treatment of both the fetus and the amniotic fluid is nec-
essary. As noted above, a significant amount of work is still required to optimize dose, timing,
and duration of rytvela treatment. Ongoing development of this approach should focus on
enhancing efficacy without additional adverse side-effects, in both sterile inflammation (i.e.
LPS) and in model systems wherein an active infection is established.
Limitations
Data presented herein should be interpreted in light of several considerations. Firstly, as a sur-
gical model, the impact of LPS and peptide exposures may be somewhat masked by back-
ground inflammation–with the surgery likely causing a higher background level of
inflammation. Secondly, the limited number of animals used in this study (by virtue of the
intensive experimental design) combined with the wide group standard deviations of the
ELISA results mean that these data should be interpreted with appropriate caution. Thirdly, as
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the dosing regimen adopted was exploratory and designed to inform subsequent experiments
it should not be considered optimal. Lastly, a lack of brain inflammation in the present study
restricts our ability to assess the potential neuro-protective benefits of rytvela. The reasons for
this are unclear, but may relate to the early gestational age of the fetuses used in this study, the
comparatively short period between LPS exposure and sample collection, and the region of
brain assessed.
A number of factors including the inability of LPS to cross cell-cell barriers, a lack of multi-
antigen stimulation, and an absence of viable infection mean that host responses to LPS likely
differ from viable microorganisms. The half-life of LPS in the amniotic fluid is 1.7 days [34]
and inflammation is gradually reduced without any intervention, which may not reflect clini-
cal intra-amniotic infection. Despite this limitation, results showing the rytvela administration
even 24 h following LPS exposure was associated with decreased inflammation in the AF and
fetal tissues is still significant.
Given the intensive nature of studies employing the chronically catheterized sheep model,
we were able to select only one dose of rytvela, based on the mouse literature, and were
restricted in terms of our group sizes. The timing of rytvela administration (24h after LPS) was
designed to allow capture a broad cross-section of protein, molecular and histological data
from multiple tissues over a 5-day time course. Given the ontology of intrauterine inflamma-
tion in the sheep model, studies targeting individual tissues (especially the brain) and signals at
specified time points will be required for more granular assessments. Irrespective, the data pre-
sented herein will inform future studies testing other rytvela dosing levels and timing relative
to LPS administration to optimize both. These will also compare the efficacy of fetal IV-only
vs. amniotic fluid-only administration of rytvela and need to assess the adverse effect using ryt-
vela-only model.
Conclusions
We report that administration of the peptide rytvela partially reduced fetal and amniotic fluid
inflammation following IA LPS challenge in an ovine model of chorioamnionitis. Given that
dosing was exploratory and inflammation already established, these findings may be cautiously
viewed as promising. Additional work focusing on optimizing dosing regimen may allow for a
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